SCHEMBL8084175

SCHEMBL8084175

Cc1cccc(-c2ccsc2C)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.44
ACHE P22303 1/20 0.42
ALDH1A1 P00352 2/20 0.41
MAPT P10636 1/20 0.41
EDNRB P24530 1/20 0.41
EDNRA P25101 1/20 0.41
RAB9A P51151 3/20 0.41
KMT2A Q03164 2/20 0.41
NPC1 O15118 2/20 0.41
NISCH Q9Y2I1 2/20 0.40
CHRNB4 P30926 1/20 0.40
CHRNA3 P32297 1/20 0.40
MEN1 O00255 1/20 0.40
MAOB P27338 1/20 0.39
CA12 O43570 2/20 0.39
CA9 Q16790 2/20 0.39
CNR2 P34972 4/20 0.38
CNR1 P21554 3/20 0.38
CHEK1 O14757 1/20 0.38
MAP4K4 O95819 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27472057 0.81 PLA2G10 (0.37) ACHEALDH1A1KMT2AMEN1CNR2
SCHEMBL693705 0.81 ACHE (0.42) HSD17B10ACHEMAPTKMT2ANISCH
SCHEMBL11104729 0.81 HSD17B10 (0.42) HSD17B10ACHEALDH1A1MAPTEDNRB
SCHEMBL28485713 0.81 EDNRB (0.45) HSD17B10ACHEALDH1A1MAPTEDNRB
SCHEMBL9027924 0.81 HSD17B10 (0.52) HSD17B10ACHEALDH1A1MAPTEDNRB
SCHEMBL1825367 0.79 BCAT2 (0.47) HSD17B10ALDH1A1EDNRBEDNRAKMT2A
SCHEMBL28119077 0.78 ALDH1A1 (0.44) HSD17B10ACHEALDH1A1MAPTEDNRB
SCHEMBL11916731 0.78 ALDH1A1 (0.49) HSD17B10ACHEALDH1A1MAPTEDNRB
SCHEMBL1338478 0.75 BCAT2 (0.50) HSD17B10ALDH1A1MAPTCNR2CNR1
SCHEMBL7830647 0.75 KMO (0.51) MAPTRAB9AKMT2ANPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063099-B2 Trans-3-aza-bicyclo[3.1.0]hexane derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2011-11-22 US disclosed
US-20100204285-A1 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-08-12 US disclosed
WO-2009016560-A2 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204285-A1 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES HCRTR1, HCRTR2, CNR1 HSD17B10 1686/4885ACHE 1647/4885ALDH1A1 747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.